Stockscreener 앱 받기
23.84
2.01%
0.47
시간 외 거래:
23.84
전일 마감가:
$23.37
열려 있는:
$23.02
하루 거래량:
86,967
Relative Volume:
0.86
시가총액:
$556.15M
수익:
$36,000
순이익/손실:
$-274.45M
주가수익비율:
-2.0185
EPS:
-11.8105
순현금흐름:
$-150.80M
1주 성능:
+4.06%
1개월 성능:
+12.19%
6개월 성능:
+37.17%
1년 성능:
+159.81%
1일 변동 폭
$23.02
$24.26
1주일 범위
$22.37
$25.25
52주 변동 폭
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
명칭
Lyell Immunopharma Inc
전화
650 695-0677
주소
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
23.84 | 545.18M | 36,000 | -274.45M | -150.80M | -11.81 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Needham | Buy |
| 2026-03-09 | 개시 | Citizens | Mkt Outperform |
| 2025-12-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-06-27 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-11-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-17 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | BofA Securities | Buy |
| 2021-07-12 | 개시 | Goldman | Buy |
| 2021-07-12 | 개시 | JP Morgan | Overweight |
| 2021-07-12 | 개시 | Morgan Stanley | Overweight |
모두보기
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
[EFFECT] Lyell Immunopharma, Inc. SEC Filing - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4%Should You Sell? - MarketBeat
This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Sahm
Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation - MSN
Needham & Company LLC Begins Coverage on Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
LYEL Earnings History & Surprises | EPS & Revenue Results | LYELL IMMUNOPHARMA INC (NASDAQ:LYEL) - ChartMill
Lyell Immunopharma (NASDAQ:LYEL) Cut to Strong Sell at Zacks Research - Defense World
Signal Recap: Will Lyell Immunopharma Inc outperform tech stocksQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference - Sahm
Lyell Immunopharma to Present at 25th Annual Needham Virtual Healthcare Conference - National Today
Cancer drug developer Lyell will webcast a management presentation Apr. 14 - Stock Titan
Head to Head Analysis: Lyell Immunopharma (NASDAQ:LYEL) & Mangoceuticals (NASDAQ:MGRX) - Defense World
Lyell Immunopharma registers 1.95M shares for resale (NASDAQ: LYEL) - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 9.2%Time to Buy? - MarketBeat
US Stocks Recap: How sensitive is Lyell Immunopharma Inc to inflation2026 Risk Factors & Reliable Entry Point Alerts - baoquankhu1.vn
Lyell Immunopharma (NASDAQ:LYEL) Lowered to Sell Rating by Wall Street Zen - MarketBeat
LYEL Technical Analysis & Stock Price Forecast - Intellectia AI
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL) - Seeking Alpha
H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada
Is Lyell Immunopharma Inc impacted by rising rates2026 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Lyell Immunopharma (LYEL) grants CFO 140,000 stock options - Stock Titan
Lyell Immunopharma (LYEL) CFO Shah identified as insider in Form 3 - Stock Titan
Lyell Immunopharma, Inc. $LYEL Shares Acquired by Foresite Capital Management V LLC - MarketBeat
Citizens reiterates Lyell Immunopharma stock rating on trial progress By Investing.com - ca.investing.com
Lyell Immunopharma closes $50M equity tranche, names new CFO By Investing.com - Investing.com Nigeria
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update - MarketBeat
Lyell Immunopharma: Q4 Earnings Snapshot - theheraldreview.com
Lyell Immunopharma 2025 Annual Report: Advancing Next-Generation CAR T-Cell Therapies for Cancer Treatment - Minichart
Lyell Immunopharma 2025 Financial Results: Annual Loss of $274.4MNews and Statistics - indexbox.io
Lyell Immunopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lyell Immunopharma (NASDAQ:LYEL) Releases Earnings Results, Misses Expectations By $5.53 EPS - MarketBeat
Lyell Immunopharma: Fourth Quarter Financial Results Overview - Bitget
Lyell Immunopharma misses Q4 revenue estimates - TradingView
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - The Manila Times
LYEL: Pivotal CAR T-cell trials show strong efficacy, with key data updates and solid funding ahead - TradingView
ARCH Venture funds add Lyell (LYEL) stake with 488,090-share buy - Stock Titan
ARCH Venture Fund XIII boosts Lyell (LYEL) stake with 488K-share purchase - Stock Titan
Lyell Immunopharma Appoints Smital Shah as Chief Financial and Business Officer Effective March 2026 - Minichart
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap UpShould You Buy? - MarketBeat
Lyell Immunopharma, Inc. announced that it has received $99.999968 million in funding - marketscreener.com
Citizens Initiates Coverage on LYEL with Market Outperform Ratin - GuruFocus
Lyell Immunopharma (NASDAQ:LYEL) Now Covered by Citizens Jmp - MarketBeat
Lyell names Smital Shah as Chief Financial and Business Officer - TradingView
Lyell Immunopharma (NASDAQ: LYEL) hires Smital Shah as finance chief - Stock Titan
Lyell Immunopharma, Inc. Appoints Smital Shah as Chief Business Officer and Principal Financial Officer, Effective March 9, 2026 - marketscreener.com
Lyell Immunopharma Announces Closing of Additional $50 - GlobeNewswire
Citizens initiates Lyell Immunopharma stock at outperform, $34 target - Investing.com South Africa
Citizens initiates Lyell Immunopharma stock at outperform, $34 target By Investing.com - Investing.com Australia
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer - The Globe and Mail
HC Wainwright & Co. Maintains Lyell Immunopharma (LYEL) Neutral Recommendation - MSN
Take Profit: Will Lyell Immunopharma Inc benefit from rate cutsTrade Volume Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Lyell Immunopharma Inc (LYEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):